



ASX ANNOUNCEMENT

Release of Shares from Escrow

MELBOURNE, Australia (22 August 2023) – Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) wishes to advise that, in accordance with ASX Listing Rule 3.10A and as stated in the Prospectus dated 7 June 2021, 40,124,915 fully paid ordinary shares will be released from voluntary escrow on 31 August 2023.

These shares are already quoted on ASX.

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

**Media Contacts:**

Matthew Wright – Australia, Lumos
Director, NWR Communications
matt@nwrcommunications.com.au
+61 (0) 451 896 420

Investor Contact:

Matthijs Smith – Lumos Diagnostics
ir@lumosdiagnostics.com
+61 3 9087 1598

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205
+61 3 9087 1598